Narayan Memorial Hospital Behala successfully conducted Antibody Cocktail Therapy
News Desk, News Nation 360: Narayan Memorial Hospital announced that they have successfully implemented Antibody Cocktail therapy on two of its patients. The patients are keeping well and are without any further complications. Casiririvimab and Imdevimab are indicated for restricted emergency use for the treatment of mild to moderate Covid-19 in patients who are at high risk of severe COVID 19. NMH is partnering with Cipla Limited in addressing the unmet patient need and look toward leveraging this innovative treatment for the people of Kolkata. The antibody cocktail (Casirivimab and Imdevimab) is a medical product that can be procured subject to a medical prescription by a registered medical practitioner. Casirivimab and Imdevimab may only be administered in settings in which health care providers have immediate access to medications to treat an infusion reaction, such as anaphylaxis. The intravenous administration takes about 20 to 30 minutes. For the subcutaneous route, four syringes of 2.5 ml (2 each of Casirivimab & Imdevimab) need to be administered concurrently at four different sites on the abdomen or thigh. Patients should be monitored during the infusion and observed for at least one hour after the completion of the infusion and 15--30 minutes after the subcutaneous injection. Each pack of Antibody Cocktail (Casirivimab and Imdevimab) contains one vial of Casirivimab and one vial of Imdevimabtotaling 2400 mg of the antibody cocktail (one vial of Casirivimab (1200 mg) and one vial of Imdevimab (1200 mg)). Each pack can treat two patients as the dosage per patient is a combined dose of 1200 mg (600 mg of Casirivimab and 600 mg of Imdevimab) administered by intravenous infusion or subcutaneous route. The vials need to be stored at 2°C to 8°C. If opened for the first patients’ dose, a vial can be used for the second patients’ dose within 48 hours if stored at 2°C to 8°C. The price for each patient dose (a combined dose of 1200 mg (600 mg of Casirivimab and 600 mg of Imdevimab) will be INR 59,750 inclusive of all taxes. The maximum retail price for the multidose pack (each pack can treat two patients) is INR 119,500 inclusive of all taxes. On the occasion Suparna Sengupta, CEO, Narayan Memorial Hospital expressed that they are now at par with other cities in India to provide broader, equitable access to this innovative treatment. They are thankful to Cipla for bringing it to Kolkata and Narayan Memorial Hospital, the youngest but dedicated Hospital towards serving patients in the ablest manner. They are optimistic that the availability of Antibody Cocktail (Casirivimab and Imdevimab) in India can help in minimizing hospitalisation, ease the burden on healthcare systems and play a key role in the treatment of high-risk patients before their condition worsens. Dr Subhrojyoti Bhowmick, Clinical Trial Expert mentioned that the antibody cocktail (Casirivimab and Imdevimab) is to be administered for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age or older, weighing at least 40 kg) who are confirmed to be infected with SARS-COV2 and who are at high risk of developing severe COVID-19 disease and do not require oxygen. It has been shown to help these high-risk patients before their condition worsens, reducing the risk of hospitalisation and fatality by 70% and shortening the duration of symptoms by four days.
Pic : Courtesy
Report : Anustup Kundu